Abstract:Background and purpose: Gene transfer with recombinant non-viral vectors encoding vasodilator proteins, Such as endothelial nitric oxide synthase (eNOS), may be a preferential choice in gene therapy of artery restenosis following angioplasty, stent or anastomosis. However, the transfection rate of a non-viral vector, the harmful effects of eNOS transfection on endothelial cells (EC)and the control release of nitric oxide (NO) have been controversial. We designed the eukaryotic expression vector pcDNA3.1-eNOS to study the regulated expression of eNOS (in the presence of various chemical agents) and to evaluate the exogenous NO effect on EC proliferation in vitro.Methods: The full-length human eNOS cDNA was inserted into the EcoRI cloning site of the pcDNA3.1 expression plasmid and the eNOS direction was tested by restriction enzyme digestion with XhoI to construct recombinant pcDNA3.1-eNOS. After co-transfection of pcDNA3.1-eNOS with pcDNA3.0-EGFP mediated by cationic liposomes into Human umbilical vein endothelial cells (ECV304), the transfection rate and the effect on ECV304 proliferation were calculated by fluorescence microscopy and flowcytometry. eNOS mRNA and protein were detected by reverse transcription-PCR (RT-PCR) and immunofluorescence, respectively. The eNOS activity, NO release and changes of the relevant cells growth curve were assessed after treating the transfected cells with four independent factors including ie Ca2+, L-arginine (L-Arg), Ethylene Diamine Tetraacetic Acid (EDTA) and N-nitro-L-arginine methylester (L-NAME). In addition, we examined the nontransfected cells status by isolated sodium nitroprusside (SNP) treatment.Result: eNOS cDNA was inserted into pcDNA3.1 in die proper direction. RT-PCR analysis showed that pcDNA3.1-eNOS transfected cells could express eNOS mRNA. The rate of eNOS transfection was 39.6 +/- 3.4%. Immunofluorescence staining displayed that subcellular localisation of eNOS was most prominent in plasma membrane and per] nuclear regions of the cell. The eNOS activity of eNOS transfected cells had not increased significantly, whereas, in the presence of Call, L-Arg, EDTA, and L-NAME, the eNOS activity was 96.98 +/- 13.47, 32.57 +/- 6.39, 11.63 +/- 3.02, 15.56 +/- 7.34 U/ml respectively and the NO level was 55.34 +/- 11.19, 9.43 +/- 4.51., 2.63 +/- 1.41, 3.73 +/- 1.65 mmol/L, respectively. Meanwhile, die growth curves of EC shifted. SNP also had obvious growth-inhibiting effects on the cells. Together, the ECV304 growth curve went downward in a NO concentration-dependent manner.Conclusion: Eukaryotic expression vector pcDNA3.1-eNOS was constructed successfully with the ability to express human eNOS mRNA and protein in EC effectively. The activity of eNOS in EC could be regulated by certain exogenous factors. Ca2+ was an important factor promoting NO release and excess NO had a cytotoxic effect on EC in vitro. Controlled release of NO in vivo and polygenic measurements might be considered in more clinical gene therapy studies.

Construction of PTIE2-CREG-EGFP-N1 eukaryotic expression plasmid and its expression in mouse artery endothelial cells

Construction of a Eukaryotic Expression Vector Pegfp-C1-bmp-2

Construction and Identification of α-MHC Promoter-driven CREG Eukaryotic Expressive Plasmid

Constructing RNA interference vector carrying cellular repressor of E1A-stimulated genes in mice

Construction and Identification of Lentiviral Vector-mediated RNA Interference of Epidermal Growth Factor Receptor

Construction of pcDNA3-Endo eukaryon expression plasmid and angiogenesis inhibition in vitro

ASSA13-10-14 Cellular Repressor of E1A-Stimulated Genes Accelerates Endothelial Angiogenesis Via Integrin-Linked Kinase-PINCH-CDC42 Activation

Construction and Expression of Eukaryotic Expression Vector for I Kappa B Alpha Mutant Gene

Establishment of a mouse NIH3T3 cells line expressing cellular repressor of E1A-stimulated genes regulated by doxycycline

Construction of Eukaryotic Expression Vector for Pig (Sus scrofa)PACAP Gene and Its Expression in 3T3-L1 Cell Line

Construction of recombinant vectors introducing ubiquitous expression or tissue-specific expression in Caenorhabditis elegans

Construction and Identification of Eukaryotic Expression Vector for HCMV IE1-GFP Fusion Protein

Construction of an Angiopoietin-Like Protein 2 Expression Vector and Its Expression in Human Endothelial Cells

Construction and evaluation of recombinant plasmid containing human triggering receptor expressed on myeloid cells-1 gene]

[Construction of Recombinant Adenovirus Vector of Calcitonin Gene-Related Peptide Gene and Transfection to Neonatal Rat Cardiomyocytes].

Construction of eukaryotic expression vector of rat HAS-3 gene and its effects on chemotaxis]

Construction and Expression in HUVEC of Eukaryotic Expressed Plasmid Vector Pcmv-(Kozak) TFPI

[Construction of Expression Vector Plck-Cd69-ires-egfp and Generation of CD69 Transgenic Mice].

Construction of vector pCAG-Z-eGFP-mIR for T cell specific expression of mouse IR

Experimental Study of Recombinant Aukaryotic Expression Vector of Human Enos in ECV304 Cells

Construction of recombinant eukaryotic expression vector pEGFPN1-GDNF and its expression